MBX · XBRL financial data
MBX Biosciences financial statements, every fiscal year
The same tables from 2 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (MBX's year ends in late December)
| In thousands of dollars | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|
| Research and development | 57,415 | 79,159 |
| General and administrative | 10,779 | 18,896 |
| Total operating expenses | 68,194 | 98,055 |
| Operating income (loss) | (68,194) | (98,055) |
| Income tax expense (benefit) | 0 | 0 |
| Net income (loss) | (61,922) | (86,971) |
| Earnings per share, basic USD per share | (5.82) | (2.38) |
| Earnings per share, diluted USD per share | (5.82) | (2.38) |
| Weighted average shares, basic thousands of shares | 10,643 | 36,506 |
| Weighted average shares, diluted thousands of shares | 10,643 | 36,506 |
Balance sheet
CSVFiscal years (MBX's year ends in late December)
| In thousands of dollars | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|
| Cash and cash equivalents | 49,351 | 75,289 |
| Marketable securities | 212,798 | 298,416 |
| Prepaid and other current assets | 5,137 | 7,834 |
| Total current assets | 267,286 | 381,539 |
| Property and equipment, net | 1,080 | 2,735 |
| Right-of-use asset | 119 | 487 |
| Total assets | 268,535 | 385,144 |
| Accounts payable | 5,335 | 2,977 |
| Accrued liabilities | 5,545 | 12,346 |
| Total current liabilities | 11,051 | 15,495 |
| Lease liability, non-current | 0 | 424 |
| Total liabilities | 11,093 | 15,921 |
| Accumulated deficit | (137,505) | (224,476) |
| Total stockholders' equity | 257,442 | 369,223 |
| Total liabilities and equity | 268,535 | 385,144 |
| Common shares outstanding (cover page) thousands of shares | 33,424 | 47,510 |
Cash flows
CSVFiscal years (MBX's year ends in late December)
| In thousands of dollars | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|
| Net income (loss) | (61,922) | (86,971) |
| Stock-based compensation | 5,222 | 8,677 |
| Net cash from operating activities | (54,681) | (79,949) |
| Purchases of property and equipment | 874 | 1,929 |
| Net cash from investing activities | (160,595) | (83,705) |
| Proceeds from issuing common stock | — | 601,700 |
| Net cash from financing activities | 234,104 | 189,592 |
| Net change in cash | 18,828 | 25,938 |
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| MBX Biosciences | 54,124 | not reported | (22,622)* | 48.2M | 18.5 quarters | 10-QJun 30, 2026 |
| Heron Therapeutics | 20,721 | not reported | (2,213)* | 189.9M | 19.3 quarters | 10-QJun 30, 2026 |
| Aldeyra Therapeutics | 45,090 | not reported | (4,589)* | 60.3M | 9.8 quarters | 10-QJun 30, 2026 |
| Annexon | 199,270 | not reported | (48,007)* | not reported | 4.4 quarters | 10-QJun 30, 2026 |
| Sagimet Biosciences | 165,896 | not reported | (11,099)* | not reported | 21.6 quarters | 10-QJun 30, 2026 |
| DBV Technologies | 165,700 | 1,600 | (51,500)* | 314.4M | 3.2 quarters | 10-QSep 30, 2026 |
| Corvus Pharmaceuticals | 18,905 | not reported | (15,398)* | 84.1M | 14.0 quarters | 10-QJun 30, 2026 |
| Lifecore Biomedical | 23,035 | 25,322 | 6,946* | 37.9M | — | 10-QSep 30, 2026 |
| Verastem | 136,353 | 40,078 | (43,909)* | 90.6M | 3.1 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.